MADRIGAL PHARMACEUTICALS, INC. SEC Filings

Madrigal Pharmaceuticals, Inc. (MDGL) received a Rule 144 notice from officer Shannon Kelley covering a planned sale of 664 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq Stock Market. The shares relate to a Restricted Stock Unit grant acquired on 08/15/2026 and vesting on 08/17/2026.

The filing states that the sale represents a sell-to-cover transaction to satisfy tax withholding obligations arising from the RSU vesting, not a discretionary sale of additional shares.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported equity compensation grants to director John C. Reed. He received 647 shares of Common Stock as restricted stock units that vest 50% on August 15, 2027 and 50% on August 15, 2028, subject to continued service. He also received a stock option for 1,078 shares at an exercise price of $507.56 per share, expiring August 15, 2036, vesting 50% on August 15, 2027 and 12.5% at the end of each successive three-month period for four periods thereafter, contingent on continued service.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an initial ownership report for John C. Reed, who is identified as a director of the company. This Form 3 does not list any stock or derivative holdings and reports no transactions. The filing also references an Exhibit 24 Power of Attorney authorizing filing actions.

Madrigal Pharmaceuticals, Inc. expanded its Board of Directors from eight to nine members and elected John C. Reed, M.D., Ph.D. as a Class II director effective August 11, 2026, with a term expiring at the 2027 annual meeting. He was appointed to the Board’s Science and Technology Committee. As a non-employee director, he will receive an annual cash retainer of $50,000 plus $10,000 annually for committee service, under Madrigal’s Non-Employee Director Compensation Policy. In connection with his appointment, he will receive an equity grant valued at $675,000, split equally between nonqualified stock options and restricted stock units under the 2026 Stock Plan, subject to multi-year vesting tied to continued service. Madrigal highlighted Dr. Reed’s current leadership role at Johnson & Johnson and his extensive biopharmaceutical and research background, and reiterated its focus on Rezdiffra, the first medication approved by the FDA and European Commission for MASH with fibrosis stages F2 to F3.

Madrigal Pharmaceuticals reported continued commercial ramp of Rezdiffra for MASH. Net product revenue reached $364.3 million in Q2 2026 and $675.6 million for the first half of 2026, up from $212.8 million and $350.1 million a year earlier, respectively. The company still posted a net loss of $57.9 million for Q2 and $152.3 million for the first half, driven by higher cost of sales, research and development, and selling, general and administrative expenses, including rising stock-based compensation.

At June 30, 2026, Madrigal held $838.9 million in cash, cash equivalents, restricted cash and marketable securities and carried a $350 million senior secured term loan bearing interest at 8.45%, with a covenant requiring at least $100 million of unrestricted cash. Management expects existing liquid resources to fund operations for more than one year. The company recorded a $10.4 million inventory write-down and continues to invest heavily in MASH pipeline expansion through large global licensing deals (CSPC, Pfizer, Ribocure, Arrowhead) while advancing the MAESTRO-NASH outcomes programs intended to support full approvals and broader Rezdiffra indications.

Madrigal Pharmaceuticals reported second-quarter 2026 Rezdiffra net revenues of $364.3 million, up 71% from $212.8 million a year earlier, with more than 49,000 patients on therapy and nearly $1.3 billion in trailing-12-month net sales.

The company highlighted three new U.S. resmetirom patents expected to protect key uses into 2042–2045 and initiated first-in-human dosing for oral GLP-1 candidate MGL-2086 in a Phase 1 trial supporting combination MASH therapy. Operating expenses rose to $420.6 million, leading to a net loss of $57.9 million, while cash, cash equivalents, restricted cash and marketable securities totaled $838.9 million as of June 30, 2026.

BlackRock, Inc. reports its beneficial ownership of common stock of Madrigal Pharmaceuticals, Inc. as of June 30, 2026. BlackRock beneficially owns 1,067,346 shares of common stock, representing 4.6% of the class. It holds 1,039,228 shares with sole voting power and all 1,067,346 shares with sole dispositive power, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single person has more than five percent of Madrigal’s outstanding common shares.

Madrigal Pharmaceuticals President and CEO William John Sibold earned 50,000 shares of common stock on July 17, 2026 after meeting performance and service conditions under a one-time sign-on Performance RSU award. On July 20, 2026, the issuer sold 2,500 of these shares on his behalf in multiple automatic transactions at weighted-average prices between $542.22 and $555.10 per share to cover tax withholding obligations, and these sales were not at Sibold's discretion. The company is irrevocably obligated to issue the remaining earned shares to him on September 8, 2029.

Madrigal Pharmaceuticals, Inc. filed a notice of proposed sale of common stock under Form 144. The filing covers 2,500 shares of common stock held through Morgan Stanley Smith Barney LLC, with a proposed sale date of July 20, 2026 on the Nasdaq Stock Market. These shares were acquired upon the vesting of Performance Restricted Stock Units on July 17, 2026.